Abstract 342P
Background
Palonosetron (PALO) is a second generation 5HT-3 receptor antagonist recommended as a preferred drug for high-emetogenic chemotherapies. PALO 0.25 mg has been reported to be as effective as 0.75 mg with less adverse events, such as constipation, when used alone or in combination with dexamethasone (DEX). The efficacy and safety of PALO 0.25 mg compared to 0.75 mg in combination with aprepitant (APR) plus DEX in patients (pts) with esophageal cancer remain unclear.
Methods
We retrospectively evaluated the efficacy and safety of PALO 0.25 mg versus 0.75 mg in combination with APR plus DEX in pts with localized or metastatic esophageal cancer who received cisplatin (CDDP)-containing chemotherapy between Nov. 2015 and Mar. 2017 at our institution. Complete response was defined as no emetic episodes and no rescue medication use.
Results
This study enrolled 58 and 55 pts who received PALO 0.25 mg and 0.75 mg. The baseline characteristics were similar between both groups. Sixteen (28%) and 24 (44%) pts received triplet regimen (docetaxel, CDDP and 5-fluorouracil), respectively. The complete response rates were 72% for 0.25 mg and 62% for 0.75 mg, with no significant difference (odds ratio [OR] = 0.62, p = 0.23). Percentages of no nausea was also similar with 40% and 33%, respectively (OR = 0.74, p = 0.44). Grade 2-3 constipation and any grade of aspartate aminotransferase increase were more frequently observed in 0.75 mg group (38% vs. 58%, p < 0.05; 7% vs. 22%, p < 0.05). In univariate and multivariate analyses, no association between baseline characteristics, including dose of PALO, and complete response rate was observed. Meanwhile, PALO 0.75 mg, older age, localized disease, and tobacco consumption were significantly associated with grade 2 or more constipation (OR = 0.28, p < 0.01; OR = 0.28, p < 0.01; OR = 3.09, p < 0.05; OR = 0.27, p < 0.05).
Conclusions
PALO 0.25 mg in combination with APR plus DEX may contributed to the decrease in constipation in pts with esophageal cancer who received CDDP-containing chemotherapy without compromising the anti-emetic effect compared to 0.75 mg.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
National Cancer Center.
Funding
Has not received any funding.
Disclosure
Y. Nakamura: Research grant/Funding (institution): Taiho Pharmaceutical. H. Taniguchi: Honoraria (self): Bayer; Honoraria (self): Sanofi; Honoraria (self), Research grant/Funding (institution): Takeda; Honoraria (self): Chugai; Honoraria (self): Taiho Pharmaceutical; Honoraria (self): Lilly Japan; Honoraria (self): Merck Serono; Honoraria (self): Yakult Honsha; Honoraria (self): MBL; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): MSD; Honoraria (self), Research grant/Funding (institution): Novartis; Honoraria (self), Research grant/Funding (institution): Daiichi-Sankyo; Honoraria (self): Mitsubishi Tanabe Pharma; Honoraria (self): Nippon Kayaku; Research grant/Funding (institution): Sumitomo-Dainippon Pharma; Research grant/Funding (institution): Array BioPharma; Research grant/Funding (institution): MSD Oncology; Research grant/Funding (institution): Ono Pharmaceutical; Research grant/Funding (institution): Sysmex. T. Kojima: Honoraria (self), Research grant/Funding (institution): Ono Pharmaceutical; Advisory/Consultancy, Research grant/Funding (institution): MSD; Research grant/Funding (institution): Astellas Amgen BioPharma; Research grant/Funding (institution): Chugaiseiyaku; Research grant/Funding (institution): Parexel; Research grant/Funding (institution): Shionogi; Advisory/Consultancy: Bristol-Myers Squibb Company; Advisory/Consultancy: Merck Biopharma; Honoraria (self): Oncolys BioPharma. T. Yoshino: Research grant/Funding (institution): Novartis Pharma; Research grant/Funding (institution): MSD; Research grant/Funding (institution): Sumitomo Dainippon Pharma; Research grant/Funding (institution): Chugai; Research grant/Funding (institution): Sanofi; Research grant/Funding (institution): Daiichi-Sankyo; Research grant/Funding (institution): Parexel International; Research grant/Funding (institution): Ono Pharmaceutical; Research grant/Funding (institution): GlaxoSmithKline. All other authors have declared no conflicts of interest.
Resources from the same session
349P - Proteinuria in patients treated with ramcirumab increases the risk of renal dysfunction
Presenter: Kenta Hayashino
Session: e-Poster Display Session
350P - Rheumatologic immune related adverse events (irAEs) secondary to immune checkpoint inhibitor (ICI) therapy: A Western Australia experience
Presenter: Azim Khan
Session: e-Poster Display Session
351P - Valvular heart diseases in patients treated for breast cancer
Presenter: Ekaterina Kushnareva
Session: e-Poster Display Session
352P - Reproductive system disorders following chemotherapy in patients with breast cancer in Yogyakarta, Indonesia
Presenter: Irfan Haris
Session: e-Poster Display Session
353P - Survey for geriatric assessment in practising oncologists in India
Presenter: Vikas Talreja
Session: e-Poster Display Session
354P - Knowledge, perception, and attitude of oncology-related healthcare providers on complementary and alternative medicine (CAM)
Presenter: Chih Kiang Tan
Session: e-Poster Display Session
355P - Impact of comorbidities and rurality on treatment commencement, completion and outcomes, and health related quality of life, for geriatric oncology patients: Preliminary findings from a regional Australian study
Presenter: Mathew George
Session: e-Poster Display Session
357P - Comparison between immunotherapy and chemotherapy as neoadjuvant setting in resectable non-small cell lung cancer: A systematic review and meta-analysis of prospective trials
Presenter: Chao Zhang
Session: e-Poster Display Session
358P - Adjuvant tyrosine kinase inhibitors in non-squamous non-small cell lung cancer with EGFR driver mutations: An updated meta-analysis of randomized trials
Presenter: Joanmarie Balolong-Garcia
Session: e-Poster Display Session
359P - The role of adjuvant targeted therapy for postoperative EGFR mutant non-small cell lung cancer: A network meta-analysis
Presenter: Guang Ling Jie
Session: e-Poster Display Session